NOVO-DIPIRADOL TAB 75MG TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

DIPYRIDAMOLE

可用日期:

NOVOPHARM LIMITED

ATC代码:

B01AC07

INN（国际名称）:

DIPYRIDAMOLE

剂量:

75MG

药物剂型:

TABLET

组成:

DIPYRIDAMOLE 75MG

给药途径:

ORAL

每包单位数:

100/500

处方类型:

Prescription

治疗领域:

MISCELLANEOUS VASODILATATING AGENTS

產品總結:

Active ingredient group (AIG) number: 0106621003; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2005-08-10

产品特点

PRODUCT MONOGRAPH
Pr
NOVO-DIPIRADOL (dipyridamole) 25, 50, 75, 100 mg Tablets
Pr
DIPYRIDAMOLE FOR INJECTION (dipyridamole) 5 mg/mL, USP
Coronary Vasodilator
Inhibitor of Platelet Adhesion and Aggregation
Novopharm Limited
Date of Preparation:
30 Novopharm Court
October 26, 2006
Toronto, Ontario
M1B 2K9
Control No. 107491
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL
USE.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
3
WARNINGS AND
PRECAUTIONS.........................................................................................
4
ADVERSE
REACTIONS...........................................................................................................
5
DRUG INTERACTIONS
...........................................................................................................
8
DOSAGE AND
ADMINISTRATION.......................................................................................
9
OVERDOSAGE
.........................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 10
STORAGE AND
STABILITY.................................................................................................
11
SPECIAL HANDLING INSTRUCTIONS
..............................................................................
11
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 11
PART II: SCIENTIFIC INFORMATION
...............................................................................
13
PHARMACEUTICAL
INFORMATION.........................................................